Identifying the Effects of GLP-1 Medications Among Individuals with Cardiovascular, Kidney and Metabolic Disease Grant

The American Heart Association is inviting proposals for research on the effects of GLP-1 and GIP agonists in individuals with cardiovascular, kidney, and metabolic diseases. This initiative aims to explore how these medications can alleviate the CKM burden. Researchers with expertise in causal inference, machine learning, and cardiovascular research are encouraged to apply, particularly those working in multidisciplinary teams and leveraging various data sources.

Note: 1) Letters of Intent are mandatory and are due on the deadline indicated above for Letter of Inquiry. 2) Applications invited to submit a proposal (Full Proposal) are chosen from the Letters of Intent.
The purpose of this Request for Proposal (RFP) announcement is to fund research focused on the potential contribution of GLP-1/GIP agonists to reducing the CKM burden in the coming years.
We invite proposals for a research project focused on evaluating the effects of GLP-1 and/or GIP agonists among individuals with cardiovascular, kidney, and metabolic disease (CKM) and/or obesity.
Proposals are welcomed from researchers with experience in causal inference methods, machine learning, and cardiovascular research. Collaborative proposals involving multidisciplinary teams are encouraged.
Proposals are encouraged to leverage data sources including de-identified claims data, electronic health records and prospective cohort studies.

Eligibility

You must be a member of this organization to apply for this award - become a member.